Patrick Y Wen

Patrick Y Wen

UNVERIFIED PROFILE

Are you Patrick Y Wen?   Register this Author

Register author
Patrick Y Wen

Patrick Y Wen

Publications by authors named "Patrick Y Wen"

Are you Patrick Y Wen?   Register this Author

100Publications

2740Reads

20Profile Views

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma.

Cancer Res 2019 Oct 15;79(19):5088-5101. Epub 2019 Aug 15.

Brain Tumor Center, Departments of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-0325DOI Listing
October 2019

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.

Clin Cancer Res 2019 Aug 7;25(16):4993-5001. Epub 2019 Jun 7.

Dana-Farber Program in Regulatory Science, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0820DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697596PMC
August 2019

Thrombotic Complications in Gliomas.

Semin Thromb Hemost 2019 Jun 30;45(4):326-333. Epub 2019 Apr 30.

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1687892DOI Listing
June 2019

Local control after brain-directed radiation in patients with cystic versus solid brain metastases.

J Neurooncol 2019 Apr 4;142(2):355-363. Epub 2019 Feb 4.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03106-1DOI Listing
April 2019

Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.

CNS Oncol 2019 03 26;8(1):CNS28. Epub 2019 Feb 26.

Department of Medical Oncology, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2018-0007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499019PMC
March 2019

The lomustine crisis: awareness and impact of the 1500% price hike.

Neuro Oncol 2019 Jan;21(1):1-3

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303421PMC
January 2019

Imaging and diagnostic advances for intracranial meningiomas.

Neuro Oncol 2019 Jan;21(Supplement_1):i44-i61

Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article/21/Supplemen
Publisher Site
http://dx.doi.org/10.1093/neuonc/noy143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347083PMC
January 2019

Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.

AJR Am J Roentgenol 2018 12 17;211(6):1342-1347. Epub 2018 Oct 17.

1 Department of Radiology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.

View Article

Download full-text PDF

Source
https://www.ajronline.org/doi/10.2214/AJR.18.19988
Publisher Site
http://dx.doi.org/10.2214/AJR.18.19988DOI Listing
December 2018

PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.

Neurology 2018 10 31;91(14):e1355-e1359. Epub 2018 Aug 31.

From the Laura and Isaac Perlmutter Cancer Center (S.C.K.), Brain Tumor Center, NYU Langone Medical Center, New York; Dana-Farber Cancer Institute (L.P.C., D.H., M.R., L.N., E.Q.L., D.A.R., P.Y.W.), Center for Neuro-Oncology; and Department of Radiology (R.H., P.U.), Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006283DOI Listing
October 2018

The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology.

Neuro Oncol 2018 08;20(9):1162-1172

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071649PMC
August 2018

Antiangiogenic Therapy of High-Grade Gliomas.

Prog Neurol Surg 2018 25;31:180-199. Epub 2018 Jan 25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000467379DOI Listing
August 2018

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.

Neurology 2018 08 27;91(9):403-413. Epub 2018 Jul 27.

From the University of Rochester (J.S.G., M.P.M., R.H.D.), NY; MetroHealth Medical Center (J.B.), Case Western Reserve University, Cleveland, OH; University of Milano-Bicocca (G.C.), Monza, Italy; MD Anderson Cancer Center (P.M.D.), Houston, TX; Milkin Institute School of Public Health (S.E.), George Washington University, Washington, DC; Division of Oncology Products (L.H.), US Food and Drug Administration, Silver Spring; National Institutes of Health (A.O.), Bethesda, MD; Virginia Commonwealth University (A.G.S.), Richmond; Mundipharma R&D Limited (D.D.-P.), Cambridge, UK; Université Laval (L.R.G.), Québec, Canada; Washington University (S.H.), St. Louis, MO; Regenacy Pharmaceuticals (M.J.), Boston; Analgesic Solutions (N.P.K.), Natick; Tufts University (N.P.K.), Boston, MA; Mayo Clinic (C.L.), Rochester, MN; Dana-Farber/Brigham and Women's Cancer Center (P.R., P.Y.W.) and Beth Israel Deaconess Medical Center (R.F.), Harvard Medical School, Boston, MA; University of Michigan (E.M.L.S.), Ann Arbor; and University of Washington (D.C.T.), Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133627PMC
August 2018

The Interface Between Neurology and Oncology.

Neurol Clin 2018 08 13;36(3):xiii-xiv. Epub 2018 Jun 13.

Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, D2, Boston, MA 02215, USA; Division of Cancer Neurology, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ncl.2018.05.001DOI Listing
August 2018

Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?

Neuro Oncol 2018 07;20(8):1144

Center for Neuro-Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280142PMC
July 2018

Toward methylation-based classification of central nervous system tumors.

Neuro Oncol 2018 04;20(5):579-581

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Broad Institute of Harvard and MIT, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892157PMC
April 2018

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.

Nat Commun 2018 04 16;9(1):1474. Epub 2018 Apr 16.

Department of Neurology, Massachusetts General Hospital, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, Harvard Medical School, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-03905-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902553PMC
April 2018

Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?

Curr Treat Options Neurol 2018 Apr 18;20(5):14. Epub 2018 Apr 18.

Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11940-018-0499-0DOI Listing
April 2018

Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Neuro Oncol 2018 03;20(4):457-471

UCLA Neuro-Oncology Program, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article/20/4/457/448
Publisher Site
http://dx.doi.org/10.1093/neuonc/nox193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909663PMC
March 2018

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.

Lancet Oncol 2018 03;19(3):e173-e180

Department of Neurology, Leiden University Medical Center, Leiden, Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30004-4DOI Listing
March 2018

Adjuvant treatments for ependymomas.

J Neurosurg Sci 2018 Feb 22;62(1):71-77. Epub 2017 Sep 22.

Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA -

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0390-5616.17.04211-4DOI Listing
February 2018

Imaging in neuro-oncology.

Ther Adv Neurol Disord 2018 28;11:1756286418759865. Epub 2018 Feb 28.

Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02445, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286418759865DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833173PMC
February 2018

Imaging Criteria in Neuro-oncology.

Semin Neurol 2018 02 16;38(1):24-31. Epub 2018 Mar 16.

Department of Neurology and Neurooncology, University Medical Center, German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1627468
Publisher Site
http://dx.doi.org/10.1055/s-0038-1627468DOI Listing
February 2018

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Neuro Oncol 2018 01;20(2):249-258

Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777496PMC
January 2018

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Neuro Oncol 2018 01;20(2):259-267

The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W., J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California San Francisco, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.P., J.H., R.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777491PMC
January 2018

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

J Clin Oncol 2018 01 26;36(1):7-13. Epub 2017 Oct 26.

Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands; Jean Charles Soria, Institut Gustave Roussy, University of Paris-Sud, and University of Paris-Saclay, Villejuif, France; Patrick Y. Wen, Dana-Farber Cancer Institute, Boston, MA; Christoph Zielinski, Comprehensive Cancer Center, Medical University Vienna; Vienna, Austria; and Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, and Fatima Rangwala, Novartis Oncology, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.6785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791845PMC
January 2018

Meeting Update-Society for Neuro-Oncology 2017 Annual Meeting.

Neuro Oncol 2018 01;20(2):156-159

Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center and Division of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777479PMC
January 2018

The siren song of bevacizumab: swan song or clarion call?

Neuro Oncol 2018 01;20(2):147-148

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777485PMC
January 2018

2016 World Health Organization Classification of Central Nervous System Tumors.

Continuum (Minneap Minn) 2017 12;23(6, Neuro-oncology):1531-1547

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CON.0000000000000536DOI Listing
December 2017

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Neuro Oncol 2017 Nov;19(12):1688-1697

Departments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Product Development, Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
http://academic.oup.com/neuro-oncology/article/19/12/1688/38
Publisher Site
http://dx.doi.org/10.1093/neuonc/nox092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716072PMC
November 2017

Transition: Message from the Editor-in-Chief.

Authors:
Patrick Y Wen

Neuro Oncol 2017 11;19(12):1567

Harvard Medical School, Director, Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox201DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716062PMC
November 2017

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Neuro Oncol 2017 Oct;19(11):1511-1521

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts; Department of Biostatistics, Harvard T. H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Department of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737512PMC
October 2017

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Oncotarget 2017 Oct 12;8(45):79298-79304. Epub 2017 May 12.

Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.17837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668041PMC
October 2017

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Neuro Oncol 2017 Jul;19(7):908-917

Department of Radiation Oncology, Department of Pathology, Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center (DF/BWCC), Harvard Medical School, Boston, Massachusetts; Department of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Accelerate Brain Cancer Cure (ABC2), Washington, DC; Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now312DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570228PMC
July 2017

Response Assessment in Neuro-Oncology Clinical Trials.

J Clin Oncol 2017 Jul 22;35(21):2439-2449. Epub 2017 Jun 22.

Patrick Y. Wen and Eudocia Q. Lee, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Susan M. Chang, University of California, San Francisco, San Francisco, CA; Michael A. Vogelbaum, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Martin J. Van den Bent, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; and David R. Macdonald, London Regional Cancer Program, Western University, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.7511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516482PMC
July 2017

Immunomodulation for glioblastoma.

Curr Opin Neurol 2017 06;30(3):361-369

aCenter for Neuro-Oncology bDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts cDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000451DOI Listing
June 2017

Angiogenesis inhibitors in tackling recurrent glioblastoma.

Expert Rev Anticancer Ther 2017 Jun 2;17(6):507-515. Epub 2017 May 2.

b Center for Neuro-Oncology , Dana-Farber Cancer Institute /Brigham and Women's Cancer Center , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1322903DOI Listing
June 2017

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

Neuro Oncol 2017 05;19(5):614-624

Division of Neuro-Oncology, Department of Neurological Surgery, University of California San Francisco,San Francisco, California

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464438PMC
May 2017

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Neurotherapeutics 2017 04;14(2):307-320

UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-016-0507-6
Publisher Site
http://dx.doi.org/10.1007/s13311-016-0507-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398984PMC
April 2017

How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.

Neuro Oncol 2017 04;19(4):459-460

Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/neuonc/nox041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464309PMC
April 2017

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

J Neurooncol 2017 02 16;131(3):603-610. Epub 2016 Nov 16.

Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Yawkey 9E, 55 Fruit Street, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-016-2332-5DOI Listing
February 2017

The Viral Connection to Glioblastoma.

Curr Infect Dis Rep 2017 Feb;19(2)

Harvard Medical School; Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11908-017-0563-zDOI Listing
February 2017

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.

Neuro Oncol 2017 01 31;19(1):89-98. Epub 2016 Aug 31.

UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z.); Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z., W.B.P.); Dept. of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E.); Dept. of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (W.P.M.);H. Lee Moffitt Cancer Center, Tampa, Florida (S.S.); F. Hoffman-La Roche, Ltd., Basel, Switzerland (L.E.A.); Exelixis, South San Francisco, California (D.T.A., G.M.S., C.H.); Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (A.L., P.L.N., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193027PMC
January 2017

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.

Neuro Oncol 2017 01 20;19(1):12-21. Epub 2016 Sep 20.

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (E.K.A., L.M.D.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neurology, VUmc Cancer Center, Amsterdam, Netherlands (J.C.R.); Department of Family Health, University of Texas Health Science Center, Houston, Texas (T.S.A.); Department of Neuro-Oncology, City of Health and Science Hospital, Torino, Italy (R.R.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/ Brigham and Women's Center, Boston, Massachusetts (P.W.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Leiden University Medical Center, The Hague, Netherlands (J.A.F.K.); Department of Neurosurgery, Wayne State University, Detroit, Michigan (S.M.); Department of Neurosurgery, Kyoto University School of Graduate Medicine, Kyoto, Japan (Y.A.); Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois (A.C.); Department of Epilepsy and Surgery Center, Cleveland Clinic, Cleveland, Ohio (J.G.-M.); Department of Neurology, London Health Sciences Center, London, Ontario, Canada (D.R.M.); Department of Neurosurgery, Saitama Medical University, Saitama, Japan (R.N.); Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan (A.S.); Service Neurologie Mazarin, CHU Pitie-Salpetriere, Paris, France (C.J.V.); Department of Neurology, University of Alabama, Birmingham, Alabama (P.W.); Department of Neuro-Oncology, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands (M.J.v.d.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now190DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193028PMC
January 2017

Message from the Editor-in-Chief.

Authors:
Patrick Y Wen

Neuro Oncol 2017 01;19(1)

Editor-In-Chief, Neuro-Oncology Professor of Neurology, Harvard Medical School Director, Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193035PMC
January 2017

Clinical Relevance of Steroid Use in Neuro-Oncology.

Curr Neurol Neurosci Rep 2017 01;17(1)

Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11910-017-0713-6DOI Listing
January 2017

Emerging targeted therapies for glioma.

Expert Opin Emerg Drugs 2016 Dec 14;21(4):441-452. Epub 2016 Nov 14.

b Center for Neuro-Oncology, Dana-Farber/Brigham Cancer Center, Division of Neuro-Oncology, Department of Neurology, and Harvard Medical School , Boston , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2016.1257609DOI Listing
December 2016

Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.

Magn Reson Imaging Clin N Am 2016 Nov 14;24(4):705-718. Epub 2016 Sep 14.

Division of Neuro-Oncology, Department of Neurology, Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mric.2016.06.003DOI Listing
November 2016